Immunome Inc. (IMNM)
| Bid | 8 |
| Market Cap | 772.66M |
| Revenue (ttm) | 9.04M |
| Net Income (ttm) | -292.96M |
| EPS (ttm) | -5 |
| PE Ratio (ttm) | -1.78 |
| Forward PE | -3.06 |
| Analyst | Buy |
| Ask | 9 |
| Volume | 584,188 |
| Avg. Volume (20D) | 1,130,940 |
| Open | 8.75 |
| Previous Close | 8.79 |
| Day's Range | 8.59 - 8.99 |
| 52-Week Range | 5.15 - 16.81 |
| Beta | 2.06 |
About IMNM
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 a...
Analyst Forecast
According to 5 analyst ratings, the average rating for IMNM stock is "Buy." The 12-month stock price forecast is $25, which is an increase of 181.53% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
4 weeks ago · businesswire.com
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced toda...
